跳至主要内容
临床试验/DRKS00031159
DRKS00031159招募中不适用

CLAUDIUS NIS: Multicentric, observational Cohort to evaLuate rAvUlizumab real worlD usage in patIents with aHUS - CLAUDIUS NIS

Alexion Pharma Germany GmbH0 个研究点目标入组 30 人开始时间: 2023年2月14日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1.Adult patients (18 years and above) with a diagnosis of aHUS (including those with a triggering event)
  • 2.Scheduled to start treatment with ravulizumab according to routine practice and as per SmPC, either as the initial treatment (initiation cohort) or after switch from eculizumab to ravulizumab after at least 3 months of treatment with eculizumab (switch cohort)

排除标准

  • 1.Treatment with other complement inhibitors than eculizumab
  • 2.Participation in an interventional trial (with an investigational medicinal product) in parallel or within the last 3 months before the inclusion to this study.
  • 3.Any contraindication as per SmPC of ravulizumab.

研究者

相似试验